NASDAQ: SBFMSunshine Biopharma Inc Stock
$0.93-0.28 (-23.14%)
Updated Apr 24, 2024
SBFM Price
$0.93
Fair Value Price
N/A
Market Cap
$924.91k
52 Week Low
$0.92
52 Week High
$140.00
P/E
-0.05x
P/B
0.04x
P/S
0.27x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.09M
Earnings
-$4.51M
Gross Margin
34.6%
Operating Margin
-16.49%
Profit Margin
-18.7%
Debt to Equity
0.29
Operating Cash Flow
-$9M
Beta
0.65
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SBFM Overview
Sunshine Biopharma Incorporated is a pharmaceutical company focused on the research and development of anticancer drugs. The company is developing Adva-27a to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other cancers. The drug is also intended to treat multidrug resistant cancers, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine cancer. If offers SBFM-PL4, an anti-coronavirus treatment. It also manufactures and distributes a Calcium-Vitamin D supplement called Essential-9. Sunshine was incorporated in 2014 and is headquartered in Pointe-Claire, Quebec, Canada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SBFM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SBFM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SBFM is good value based on its book value relative to its share price (0.04x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.06x)
P/B vs Industry Valuation
SBFM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SBFM due diligence checks available for Premium users.
Be the first to know about important SBFM news, forecast changes, insider trades & much more!
SBFM News
Valuation
SBFM fair value
Fair Value of SBFM stock based on Discounted Cash Flow (DCF)
Price
$0.93
Fair Value
$1.12
Undervalued by
16.63%
SBFM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SBFM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
47.66x
Market
41.27x
SBFM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.04x
Industry
2.06x
SBFM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SBFM's financial health
Profit margin
Revenue
$7.7M
Net Income
-$1.3M
Profit Margin
-16.3%
SBFM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SBFM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$27.3M
Liabilities
$6.1M
Debt to equity
0.29
SBFM's short-term assets ($24.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SBFM's short-term assets ($24.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SBFM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SBFM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$269.2k
Financing
-$30.5k
SBFM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SBFM vs Pharmaceutical Stocks
Sunshine Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.